Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
NAUT Stock Chart & Stats
$3.13
$0.07(3.48%)
At close: 4:00 PM EST
$3.13
$0.07(3.48%)
Day’s Range― - ―
52-Week Range$0.62 - $4.31
Previous CloseN/A
Volume21.91K
Average Volume (3M)394.63K
Market Cap
$396.15M
Enterprise Value$413.78M
Total Cash (Recent Filing)$103.41M
Total Debt (Recent Filing)$30.02M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Apr 28, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding126,564,476
10 Day Avg. Volume378,207
30 Day Avg. Volume394,629
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-64.00
Enterprise Value/Ebitda-7.88
Forecast
1Y Price Target
$4.00Price Target Upside27.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Proprietary Voyager Platform And External ValidationThe Voyager instrument’s public debut and favorable researcher feedback represent tangible platform validation, strengthening Nautilus’s competitive moat in high-throughput proteomics. Durable technical credibility aids long-term adoption by research and pharma partners, underpinning future instrument and consumables revenue.
Early Access Program And Tau Assay ReadinessAn earlier-than-planned Early Access program plus a validated Tau assay de-risks commercialization by collecting operator feedback, validating workflows, and proving reproducibility with partners. This iterative customer engagement improves product-market fit and reduces scaling friction for instrument and consumables rollouts.
Improved Cash Position And Reduced Burn, Runway To 2027Lowered 2025 cash burn and a $156M cash balance materially extend runway, giving management time to complete commercialization milestones. This financial buffer supports product launches and early commercial activities without immediate financing, improving the odds of execution on the multi-year growth plan.
Bears Say
Zero Reported Revenue And Persistent Net LossesNautilus has no reported product revenue and continues to record sizable net losses, indicating the business is still pre-commercial. Absent a demonstrable, scalable revenue stream, the company must rely on financing to fund operations, creating ongoing execution and dilution risk over the next several quarters.
No Sales Organization; Commercialization Execution RiskLaunching instruments and recurring consumables revenue depends on a functioning commercial engine. The current absence of a salesforce increases the risk that early interest won’t convert to orders or sustained consumables demand, lengthening time to revenue and pressuring margin recovery post-launch.
Sustained Negative Cash Flow And Weakening Asset BasePersistent negative operating and free cash flow, and accelerating free cash burn, erode financial flexibility and shareholder equity over time. If commercial ramp is delayed, the company may need additional capital, increasing dilution risk and constraining investments that support long-term margin and scale benefits.
Nautilus Biotechnolgy News
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $0.62 and its highest was $4.31 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Nautilus Biotechnolgy’s market cap is $396.15M.
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is Apr 28, 2026 which is in 19 days.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Feb 26, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.03.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -0.15.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 126,564,476 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -16.263%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Currently, no hedge funds are holding shares in NAUT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nautilus Biotechnolgy Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (27.80% Upside)
$4.00 (27.80% Upside)
Insider Transactions
Bought Shares
Worth $65.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 16.4%
Last 30 Days ▲ 16.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.20%
12-Months-Change
Fundamentals
Return on Equity
-33.64%
Trailing 12-Months
Asset Growth
-21.27%
Trailing 12-Months
Company Description
Nautilus Biotechnolgy
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
NAUT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful technical progress, strong external validation, the successful public debut of the Voyager instrument, the early launch of an Early Access Program (Tau assay) and disciplined expense reductions that improved cash burn and extended runway through 2027. Offsetting these positives are limited near-term revenue (modest 2026 services revenue targeted at ~$0.5M), no current sales organization, and a planned increase in 2026 operating expenses and cash burn as the company invests to advance commercialization. On balance, the developments point to a company transitioning from development to early customer engagement with tangible validation and a clear commercialization timeline, though revenue and commercial execution risks remain in the near term.View all NAUT earnings summariesNAUT Stock 12 Month Forecast
Average Price Target
$4.00
▲(27.80% Upside)
Technical Analysis
Ownership Overview
35.45% Insiders
2.62% Mutual Funds
40.87% Other Institutional Investors
19.07% Public Companies and
Individual Investors